KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Other Non-Current Liabilities: 2013-2025

Historic Other Non-Current Liabilities for Halozyme Therapeutics (HALO) over the last 13 years, with Sep 2025 value amounting to $71.8 million.

  • Halozyme Therapeutics' Other Non-Current Liabilities rose 77.69% to $71.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.8 million, marking a year-over-year increase of 77.69%. This contributed to the annual value of $54.8 million for FY2024, which is 45.17% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Other Non-Current Liabilities is $71.8 million, which was down 7.68% from $77.8 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Other Non-Current Liabilities ranged from a high of $130.0 million in Q2 2022 and a low of $171,000 during Q1 2022.
  • Over the past 3 years, Halozyme Therapeutics' median Other Non-Current Liabilities value was $37.7 million (recorded in 2023), while the average stood at $44.5 million.
  • In the last 5 years, Halozyme Therapeutics' Other Non-Current Liabilities slumped by 93.91% in 2022 and then skyrocketed by 17,194.15% in 2023.
  • Over the past 5 years, Halozyme Therapeutics' Other Non-Current Liabilities (Quarterly) stood at $544,000 in 2021, then spiked by 5,908.46% to $32.7 million in 2022, then rose by 15.40% to $37.7 million in 2023, then surged by 45.17% to $54.8 million in 2024, then surged by 77.69% to $71.8 million in 2025.
  • Its last three reported values are $71.8 million in Q3 2025, $77.8 million for Q2 2025, and $56.4 million during Q1 2025.